ALAudrey Lumeau

Audrey Lumeau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Audrey Lumeau has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Replication origin firing capacity indicates ATR inhibitor sensitivity

    by A. Lumeau, P. L. Pfuderer, J. A. Scarth, E. Maniati, M. A. Guscott, N. Shaikh, F. B. Copley, H. Gerdes, S. De Angelis, E. L. Alard, et al.

    Inhibitors of ATR, a central kinase controlling DNA replication origin firing and cellular checkpoints, are undergoing clinical trials, yet mechanisms underpinning sensitivity to ATR inhibitors (ATRi) and patient stratification biomarkers are lacking. Here, we perform in parallel, proteomics, transcriptomics and functional analyses and demonstrate that sensitive cancer cell lines have higher expression of DNA replication initiation factors, and exhibit higher origin firing, increased pan-nuclear γH2AX signals and cell death upon ATRi treatment. ATRi sensitivity is causally associated with origin firing rates, since we could modulate ATRi sensitivity by either up- or down-regulating origin firing capacity using CDC7 inhibition, CDK2 inhibition or CDC45 overexpression in both breast and colorectal cancer cells. High expression of replication initiation factors predicts ATRi sensitivity across cell lines from multiple cancer types and acute myeloid leukemia patient samples. This study reveals a contribution of lethal origin firing capacity to ATR sensitivity, providing key steps towards developing a multimodal clinically applicable biomarker.


  • Le rôle de la cytidine désaminase dans le contrôle du stress réplicatif et de la résistance des cellules cancéreuses pancréatiques aux agents ciblant l'ADN

    by Audrey Lumeau

    La cytidine désaminase (CDA) est impliquée dans le recyclage des pyrimidines, en convertissant les cytidines et désoxycytidines en uridines et désoxyuridines, essentielles pour la synthèse d'ADN et d'ARN. La perte de CDA induit de l'instabilité génétique dans le syndrome de Bloom, et sa surexpression est associée à la résistance des tumeurs aux chimiothérapies à base d'analogues de désoxycytidine. Nous avons récemment découvert que la CDA est surexprimée dans les adénocarcinomes pancréatiques (PDAC), une maladie sans traitement curatif aux stades avancés et prédite comme la seconde cause de décès par cancer d'ici 2040. La perte de CDA dans des modèles expérimentaux de PDAC inhibe fortement la prolifération cellulaire et la croissance tumorale, en absence de chimiothérapie, suggérant un nouveau rôle de la CDA dans la progression des tumeurs pancréatiques. Dans ce travail de thèse, nous avons trouvé que l'expression de la CDA est associée à un enrichissement des gènes de la signature de réplication de l'ADN, dans des tumeurs pancréatiques de patients et des modèles expérimentaux. Nous démontrons ensuite que la CDA est localisée aux fourches de réplication, augmente la vitesse et l'efficacité de redémarrage des fourches de réplication. Ces effets sont strictement dépendants de l'activité désaminase de la CDA. Nous avons ensuite découvert que l'expression de CDA corrèle inversement avec le niveau de stress réplicatif des cellules et que sa déplétion est associée à l'activation la voie ATR en réponse au stress réplicatif (données transcriptomiques) et l'activation de la protéine CHK1. De plus, nous montrons que la CDA limite l'instabilité du génome, étant donné que l'expression de CDA corrèle négativement avec la formation de micronoyaux et la transmission des dommages aux cellules filles. Dans l'encyclopédie des lignées cancéreuses (CCLE), l'expression de CDA est associée à la résistance aux agents thérapeutiques ciblant l'ADN. Des études fonctionnelles montrent que la surexpression de la CDA, mais pas la CDA mutante catalytiquement inactive, protège les cellules PDAC contre la camptothécine, un inhibiteur de topoisomérase. Pour montrer le potentiel clinique de ces travaux, nous avons ciblé la CDA dans des cellules primaires de PDAC et avons trouvé que la CDA est nécessaire à la croissance des cellules primaires. Enfin, le ciblage de la CDA sensibilise ces cellules primaires à l'Oxaliplatine, inducteur d'adduits d'ADN, in vitro et in vivo étant donné que la combinaison diminue la progression tumorale. L'ensemble de nos résultats révèle pour la première fois que la CDA régule le niveau de stress réplicatif à proximité de la fourche de réplication, et qu'elle protège les cellules PDAC des agents induisant du stress réplicatif. Ainsi, ce travail de thèse propose de nouvelles stratégies thérapeutiques prometteuses basées sur le ciblage de la CDA pour combattre les résistances aux traitements dans le PDAC et créer de nouvelles opportunités thérapeutiques.

  • Open Access

    High levels of DNA replication initiation factors indicate ATRi sensitivity via excessive origin firing

    by Audrey Lumeau, Pauline Luise Pfuderer, Simone De Angelis, James Alexander Scarth, Molly Ann Guscott, Nadeem Shaikh, Findlay Bewicke Copley, Henry Gerdes, Emilie Louise Alard, Pedro Rodriguez Cutillas, et al.

    Inhibitors of ATR, a central kinase controlling DNA replication origin firing and cellular checkpoint activity, are currently in multiple clinical trials, yet mechanisms underpinning sensitivity and robust patient stratification biomarkers are lacking. We used functional genomics approaches to identify molecular mechanisms driving sensitivity to the ATR inhibitor (ATRi) ceralasertib. Replication stress-associated patterns of DNA copy number alterations identified a subset of sensitive breast cancer cell lines. In parallel, we performed proteomics, phosphoproteomics and gene expression analyses and discovered that sensitive cell lines had higher expression of DNA replication origin firing factors, and massively increased origin firing in response to ATRi. ATRi sensitivity was partly rescued upon co-treatment with XL-413, a CDC7 inhibitor that decreases origin firing. High expression of replication initiation factors correlated with ATRi sensitivity across multiple cancer types, and in acute myeloid leukemia patient samples. Together, this study reveals a novel contribution of lethal origin firing capacity in determining the sensitivity of cancer cells to ATR inhibition and demonstrates the predictive potential of mechanism-specific copy number alterations, providing key steps towards developing a multimodal clinically applicable biomarker for ATR inhibitors.


  • Open Access

    Cytidine deaminase-dependent mitochondrial biogenesis as a potential vulnerability in pancreatic cancer cells

    by Audrey Frances, Audrey Lumeau, Nicolas Bery, Marion Gayral, Lucille Stuani, Marie Sorbara, Estelle Saland, Delphine Pagan, Naïma Hanoun, Jérôme Torrisani, et al.

    Cytidine deaminase (CDA) converts cytidine and deoxycytidine into uridine and deoxyuridine as part of the pyrimidine salvage pathway. Elevated levels of CDA are found in pancreatic tumors and associated with chemoresistance. Recent evidence suggests that CDA has additional functions in cancer cell biology. In this work, we uncover a novel role of CDA in pancreatic cancer cell metabolism. CDA silencing impairs mitochondrial metabolite production, respiration, and ATP production in pancreatic cancer cells, leading to a so-called Pasteur effect metabolic shift towards glycolysis. Conversely, we find that CDA expression promotes mitochondrial biogenesis and oxidative phosphorylation, independently of CDA deaminase activity. Furthermore, we observe that patient primary cells overexpressing CDA are more sensitive to mitochondria-targeting drugs. Collectively, this work shows that CDA plays a non-canonical role in pancreatic cancer biology by promoting mitochondrial function, which could be translated into novel therapeutic vulnerabilities.


  • Open Access

    Figure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs

    by Audrey Lumeau, Nicolas Bery, Audrey Francès, Marion Gayral, Guillaume Labrousse, Cyril Ribeyre, Charlene Lopez, Adele Nevot, Abdessamad El Kaoutari, Naima Hanoun, et al.

    Figure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs

  • Open Access

    Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs

    by Audrey Lumeau, Nicolas Bery, Audrey Francès, Marion Gayral, Guillaume Labrousse, Cyril Ribeyre, Charlene Lopez, Adele Nevot, Abdessamad El Kaoutari, Naima Hanoun, et al.

    Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs

  • Open Access

    Figure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs

    by Audrey Lumeau, Nicolas Bery, Audrey Francès, Marion Gayral, Guillaume Labrousse, Cyril Ribeyre, Charlene Lopez, Adele Nevot, Abdessamad El Kaoutari, Naima Hanoun, et al.

    Figure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs

  • Open Access

    Figure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs

    by Audrey Lumeau, Nicolas Bery, Audrey Francès, Marion Gayral, Guillaume Labrousse, Cyril Ribeyre, Charlene Lopez, Adele Nevot, Abdessamad El Kaoutari, Naima Hanoun, et al.

    Figure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs

  • Open Access

    Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs

    by Audrey Lumeau, Nicolas Bery, Audrey Francès, Marion Gayral, Guillaume Labrousse, Cyril Ribeyre, Charlene Lopez, Adele Nevot, Abdessamad El Kaoutari, Naima Hanoun, et al.

    Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs

  • Open Access

    Figure S4 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs

    by Audrey Lumeau, Nicolas Bery, Audrey Francès, Marion Gayral, Guillaume Labrousse, Cyril Ribeyre, Charlene Lopez, Adele Nevot, Abdessamad El Kaoutari, Naima Hanoun, et al.

    Figure S4 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs